首页|度普利尤单抗治疗老年难治性大疱性类天疱疮5例

度普利尤单抗治疗老年难治性大疱性类天疱疮5例

扫码查看
度普利尤单抗治疗5例老年难治性大疱性类天疱疮(BP)患者.5例患者平均年龄为78.2岁,合并多种基础疾病.明确诊断后,给予其度普利尤单抗规律治疗3~5次,BP患者皮损得到控制,瘙痒明显缓解,定期随访中.度普利尤单抗是一种全人类IgG4单克隆抗体,通过与IL-4R和IL-13R-亚基的共同链结合,阻断IL-4/13信号传导途径,从而打断了 BP发病的炎症通路,其还可通过对IL-4和IL-13的直接作用和对嗜酸性粒细胞的作用导致IL-31分泌减少,从而减少外周瘙痒感觉神经元的信号传递,因此可缓解老年BP的瘙痒问题.
Dupuyuzumab Treatment of 5 Cases Elderly Refractory Bullous Pemphigoid
We report five elderly patients with refractory bullous pemphigoid treated with dupuyuzumab.The average age was 78.2 years old,and they were complicated with various basic diseases.After a definite diagnosis,the skin lesions of bullous pemphigoid were controlled and the itching was obviously relieved after the regular treatment of duprizumab for 3-5 times,and the patients were followed up regularly.Duplex monoclonal antibody is a monoclonal antibody of human IgG4-4.By binding to the common chain of IL-4R and IL-13R-subunits,it blocks the IL-4/13 signaling pathway,thus interrupting the inflammatory pathway of BP.It can also reduce the secretion of IL-31 through its direct action on IL-4 and IL-13 and its action on eosinophils,thus reducing the signal transmission of peripheral itch sensory neurons.

Old ageRefractory bullous pemphigoidDupilumab

乌日嘎、贺伟

展开 >

内蒙古医科大学附属医院皮肤科,内蒙古呼和浩特 010050

老年 难治性大疱性类天疱疮 度普利尤单抗

内蒙古自治区自然科学基金项目内蒙古医科大学面上项目

2020MS08112YKD2021MS039

2024

皮肤科学通报
西安交通大学

皮肤科学通报

CSTPCD
影响因子:0.273
ISSN:1001-8077
年,卷(期):2024.41(4)
  • 4